AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ...

AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of three indications: adults with indolent systemic mastocytosis (ISM), adults with aggressive ...

AYVAKYT will be available in 100 mg, 200 mg and 300 mg dose strengths, and the recommended starting dose is 300 mg once daily.

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Provided by PR NewswireJun 12, 2025, 10:01:00 PM Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT ...

AYVAKYT, a potent and selective inhibitor of D816V mutant KIT, is being developed to treat advanced and non-advanced forms of SM. Last month, Blueprint Medicines announced that the U.S. Food and ...

Revenues were $96.1 million in the first quarter of 2024, including $92.5 million of net product revenues from sales of AYVAKIT/AYVAKYT and $3.6 million in collaboration revenues.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses ...

The medicine is approved in the EU as AYVAKYT for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL ...